磁浮心室辅助装置市场按流量类型、装置类型、治疗用途、患者年龄层、最终用户和分销管道划分 - 全球预测（2026-2032 年）

2025 年磁浮心室辅助装置市值为 7.1528 亿美元，预计到 2026 年将成长至 7.8752 亿美元，预计到 2032 年将达到 14.8575 亿美元，复合年增长率为 11.00%。

主要市场统计数据
基准年 2025	7.1528亿美元
预计年份：2026年	7.8752亿美元
预测年份：2032年	14.8575亿美元
复合年增长率 (%)	11.00%

在临床需求、技术进步、患者照护和设备创新等因素的共同推动下，重点在于推进磁浮心室辅助装置（VAD）的实施。

磁浮心室辅助装置（VAD）结合了先进的磁浮技术和新一代心血管支援技术，为医疗专业人员提供了减少血液相容性併发症和延长装置使用寿命的途径。早期采用该装置的医疗中心强调，其无机械轴承设计以及由此带来的剪切应力降低，能够减少血液应变，从而减少溶血和血栓事件的发生。这些技术优势引起了专注于持续循环支援的多学科团队的广泛关注。

技术创新、临床实践和医疗政策调整所带来的变革性变化正在重塑磁浮心室辅助装置的模式。

多项平行变革正在重新定义临床医生、製造商和医疗保健系统对持续机械循环支援（CMCS）的理解和应用。首先，磁浮平台技术的成熟使得体积更小、效率更高、且可程式设计的设备成为可能。这项发展促使人们重新评估患者选择标准；如果设备在早期临床应用中展现出良好的安全性和血流动力学稳定性，临床医生正在探索扩大其适应症的可能性。

分析2025年美国关税对设备零件、供应链韧性和价值链策略采购决策的累积影响

2025年的关税环境迫使植入式磁浮循环辅助系统重新检视其零件筹资策略。如果关税壁垒影响采购的零件，精密轴承、高性能磁铁和电力电子装置等关键子系统将面临供应链成本上升的风险。因此，製造商和供应商正在加速供应商多元化，重点关注近岸外包和合格的替代供应商，以降低供应中断风险并维持生产进度。

关键细分洞察，重点在于按设备架构、治疗目的和使用者环境分類的不同临床、商业和营运管道

血流特性的分析突显了器械选择和临床应用的重要差异。具有连续流结构的器械，包括轴流和离心流器械，由于其紧凑的植入结构和持续的血流动力学管理，通常优先考虑长期循环支持。同时，脉动流器材在某些生理情况下仍然有用，因为节律性心臟支持可提供独特的临床益处。这些技术差异会影响手术方法、抗凝血策略和病患监测通讯协定。

以主要地区分析磁浮循环支援系统：阐明需求驱动因素、临床应用模式与政策环境

在美洲地区，先进的临床基础设施和集中式卓越中心支援新型循环支援平台的早期应用；学术医院主导研究者主导的评估；大型医疗系统则优先考虑整合式诊疗路径。这些趋势推动着严格的数据收集，并影响支付方和医疗服务提供者寻求切实改善患者预后和资源利用的采购决策。从三级医疗机构向覆盖广泛的医院网路过渡，需要考虑培训、服务网路和远端监测能力。

策略层面的公司洞察，塑造磁浮心室辅助装置领域的竞争定位、创新重点与伙伴关係结构

领先的医疗器材开发商和专业Start-Ups凭藉其独特的临床证据生成能力、磁浮和电机控制领域的智慧财产权以及生产规模优势脱颖而出。一些公司优先考虑快速推进临床应用，透过与知名心臟中心合作、开展研究者主导的註册研究和早期可行性研究来实现这一目标；而另一些公司则专注于建立稳健的供应链和可扩展的生产能力，以支持更广泛的商业性推出。工程技术型公司与成熟的心血管器材製造商之间的合作，能够在确保符合监管要求的同时，加速复杂子系统的临床应用进程。

为产业领导者提供实用建议，以协调临床证据、製造韧性和商业策略，从而成功部署磁浮

重点在于建立可靠的临床证据管道，将前瞻性临床试验与全面的註册登记相结合，以同时获取对照试验结果和真实世界表现指标。加强上市后监测，并在器材研发早期阶段就与关键意见领袖（KOL）互动，将加速临床认可，并为与支付者的讨论提供必要数据。同时，投资供应商资格合格和区域製造伙伴关係，以降低贸易波动风险，并确保重症监护环境中器械的持续供应。

调查方法说明了用于产生此分析的严谨的一手和二手调查方法、专家参与以及跨部门检验。

本研究结合了对同侪审查的临床文献、监管申报文件和器械特定技术文件的系统性回顾，以及透过访谈心臟外科医生、心臟衰竭专家、监管事务专家和製造工程师进行的定性一手研究。技术评估包括对器械结构、血液相容性以及植入流程的检验。供应链评估检验了供应商多元化策略、製造地地点以及在近期贸易政策变化背景下的物流脆弱性。

针对临床医师、製造商和医疗系统决策者，总结磁浮心室辅助装置技术策略意义的综合结论

磁浮心室辅助装置技术兼具工程创新与临床应用前景，尤其在降低机械磨损和提高血液相容性方面，与传统设计相比具有显着优势。要将技术优势转化为持续的临床疗效，需要在实证医学证据收集、临床医生培训和服务提供方面做出共同努力。同时投资于临床註册、外科培训和供应链稳健性的医疗系统和器械开发商，将更有利于为晚期心臟衰竭患者带来潜在益处。

目录

第一章：序言

第二章调查方法

• 研究设计
• 研究框架
• 市场规模预测
• 数据三角测量
• 调查结果
• 调查前提
• 调查限制

第三章执行摘要

• 首席体验长观点
• 市场规模和成长趋势
• 2025年市占率分析
• FPNV定位矩阵，2025
• 新的商机
• 下一代经营模式
• 产业蓝图

第四章 市场概览

• 产业生态系与价值链分析
• 波特五力分析
• PESTEL 分析
• 市场展望
• 上市策略

第五章 市场洞察

• 消费者洞察与终端用户观点
• 消费者体验基准
• 机会地图
• 分销通路分析
• 价格趋势分析
• 监理合规和标准框架
• ESG与永续性分析
• 中断和风险情景
• 投资报酬率和成本效益分析

第六章 美国关税的累积影响，2025年

第七章 人工智慧的累积影响，2025年

第八章磁浮心室辅助装置市场（依流量类型划分）

• 连续流
  • 轴流式
  • 离心流
• 脉动流

第九章磁浮心室辅助装置市场（依装置类型划分）

• 双心室辅助装置（BIVAD）
• 左心室辅助装置（LVAD）
• 右心室辅助装置（RVAD）

第十章 依治疗应用分類的磁浮心室辅助装置市场

• 通往復健的桥樑
• 移植桥樑
• 目的地疗法

第十一章 依病患年龄层分類的磁浮心室辅助装置市场

• 成人
• 儿童

第十二章磁浮心室辅助装置市场（依最终用户划分）

• 门诊手术中心
• 医院

第十三章磁浮心室辅助装置市场（依通路划分）

• 在线的
• 离线

第十四章磁浮辅助装置市场（按地区划分）

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十五章磁浮心室辅助装置市场（依组别划分）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十六章 各国磁浮心室辅助装置市场概况

• 我们
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

16. 美国磁浮心室辅助装置市场

第十七章：中国磁浮心室辅助装置市场

第十九章 竞争情势

• 市场集中度分析，2025年
  • 浓度比（CR）
  • 赫芬达尔-赫希曼指数 (HHI)
• 近期趋势及影响分析，2025 年
• 2025年产品系列分析
• 基准分析，2025 年
• Abbott Laboratories
• Berlin Heart GmbH
• BiVACOR, Inc.
• Calon Cardio-Technology Ltd.
• CH Biomedical, Inc.
• Cirtec Medical Corporation
• Cleveland Heart, Inc.
• Coridea, LLC
• CorWave SA
• Evaheart, Inc.
• FineHeart SA
• Leviticus Cardio Ltd.
• Magenta Medical Ltd.
• Medtronic plc
• NuPulseCV, Inc.
• ReinHeart TAH GmbH
• Sun Medical Technology Research Corp.
• Windmill Cardiovascular Systems, Inc.

The MagLev Ventricular Assist Device Market was valued at USD 715.28 million in 2025 and is projected to grow to USD 787.52 million in 2026, with a CAGR of 11.00%, reaching USD 1,485.75 million by 2032.

KEY MARKET STATISTICS
Base Year [2025]	USD 715.28 million
Estimated Year [2026]	USD 787.52 million
Forecast Year [2032]	USD 1,485.75 million
CAGR (%)	11.00%

A focused introduction to maglev ventricular assist devices that frames clinical needs, engineering advances, and the convergence of patient care and device innovation

Maglev ventricular assist devices (VADs) represent an intersection of advanced magnetic levitation engineering and next-generation cardiovascular support, offering clinicians a pathway to reduced hemocompatibility complications and improved device longevity. Early adopters emphasize that the absence of mechanical bearings and the resulting lower shear stress can translate into gentler blood handling, and consequently fewer hemolytic and thrombotic events. These technical advantages have accelerated interest among multidisciplinary teams focused on durable circulatory support.

As a result, clinical programs are driven by an imperative to extend high-quality life for patients with advanced heart failure while reducing rehospitalization burdens. In parallel, engineering teams are optimizing control algorithms, miniaturized high-speed motors, and energy-efficient power delivery to reconcile the physiological demands of continuous support with practical constraints of implantation and patient mobility. Furthermore, regulatory pathways have started to adapt to device architectures that blend mechanical innovation with software-driven control, creating a dynamic environment for evidence generation and clinical validation.

The broader landscape is also shaped by hospital procurement priorities and payer scrutiny, which increasingly favor devices demonstrating robust safety profiles and measurable impacts on patient trajectories. Consequently, stakeholders from clinicians to commercial strategists are realigning investment and trial priorities to capture the promise of maglev-based circulatory support while addressing implementation challenges in varied care settings.

Transformative shifts reshaping the maglev ventricular assist device landscape driven by technology, clinical practice, and health policy realignment

Several concurrent shifts are redefining how clinicians, manufacturers, and health systems approach durable mechanical circulatory support. First, technological maturation in magnetic levitation platforms is enabling smaller, more efficient devices that can be programmed for tailored hemodynamic profiles. This evolution is prompting a re-evaluation of patient selection criteria, with clinicians exploring expanded indications when devices exhibit favorable safety and hemodynamic stability in early clinical use.

Second, clinical practice is gravitating toward multidisciplinary care pathways that integrate advanced heart failure specialists, perfusion teams, and outpatient management protocols. These coordinated approaches improve perioperative outcomes and reduce the friction associated with long-term device management. Third, regulatory agencies are placing greater emphasis on real-world evidence and post-market safety surveillance, which encourages manufacturers to design rigorous registries and investigator-initiated studies to demonstrate sustained benefit and device reliability.

Finally, supply chain resilience and manufacturing scale are becoming strategic differentiators as health systems prefer partners capable of consistent device availability and responsive service networks. Taken together, these shifts create a landscape where technological promise must be matched by clinical evidence, robust commercialization planning, and proactive stakeholder engagement to realize the full potential of maglev ventricular assist solutions.

Analysis of the cumulative impact of United States tariffs in 2025 on device components, supply chain resilience, and strategic sourcing decisions across the value chain

The tariff landscape introduced in 2025 has necessitated reassessment of component sourcing strategies for implantable maglev circulatory support systems. Key subsystems such as precision bearings, high-performance magnets, and power electronics are sensitive to supply chain cost inflation when tariff barriers affect sourced components. As a result, manufacturers and suppliers have accelerated vendor diversification, with emphasis on nearshoring and the qualification of alternate suppliers to mitigate disruption risk and preserve production cadence.

In addition to procurement strategies, engineering teams are prioritizing design-for-manufacturability initiatives that reduce reliance on tariff-exposed subassemblies by simplifying component counts and emphasizing modularity. Regulatory and quality groups have concurrently increased supplier audits and validated secondary sources to maintain device integrity while adapting to shifting trade conditions. Moreover, commercial teams are negotiating more flexible contracts and inventory buffers with customers and distributors to absorb lead-time variability without compromising clinical availability.

While tariffs have introduced immediate cost and logistics challenges, they have also catalyzed longer-term strategic changes. Stakeholders are investing in local manufacturing capabilities, enhancing supply chain transparency, and fostering partnerships with contract manufacturers capable of producing critical components within more stable jurisdictions. This systemic response aims to preserve patient access to advanced circulatory support while ensuring business continuity amidst geopolitical and trade-induced headwinds.

Key segmentation insights that illuminate distinct clinical, commercial, and operational pathways based on device architecture, therapy purpose, and user environment

Analysis by flow characteristics highlights meaningful differences in device selection and clinical application. Devices based on Continuous Flow architectures, which include Axial Flow and Centrifugal Flow subtypes, tend to prioritize prolonged circulatory support with compact implant configurations and continuous hemodynamic delivery. In contrast, Pulsatile Flow devices remain relevant for specific physiological profiles where rhythmic cardiac assistance may offer unique clinical benefits. These technological distinctions influence surgical approach, anticoagulation strategies, and patient monitoring protocols.

Device type segmentation clarifies use-case differentiation between Bivad, Lvad, and Rvad configurations, with biventricular systems reserved for patients with multi-chamber failure while left or right ventricular assist systems address isolated chamber dysfunction. Therapy application segmentation separates clinical intent into Bridge To Recovery, Bridge To Transplant, and Destination Therapy pathways, each carrying distinct evidence requirements and follow-up regimens that affect clinical trial design and payer engagement. End user segmentation distinguishes deployment contexts between Ambulatory Surgical Centers and Hospitals, where procedural capabilities, perioperative staffing, and post-discharge care will vary significantly.

Patient age group segmentation divides clinical approaches across Adult and Pediatric populations, driving differences in device sizing, growth considerations, and long-term management strategies for younger recipients. Finally, distribution channel segmentation between Direct Sales and Distributors shapes commercialization models and service-delivery expectations, with direct channels often enabling closer clinical collaboration and distributor channels facilitating broader geographic reach and inventory management. Together, these intersecting segmentation lenses reveal clear implications for product design, clinical protocols, reimbursement strategy, and commercial prioritization.

Regional insights that clarify demand drivers, clinical adoption patterns, and policy environments across major global territories for maglev circulatory support systems

In the Americas, advanced clinical infrastructure and concentrated centers of excellence support early adoption of novel circulatory support platforms, with academic hospitals often leading investigator-initiated evaluations and large health systems prioritizing integrated care pathways. These dynamics foster rigorous data collection and influence procurement decisions as payers and providers look for tangible improvements in patient outcomes and resource utilization. Transitioning from tertiary centers to broader hospital networks requires attention to training, service networks, and remote-monitoring capabilities.

The Europe, Middle East & Africa region demonstrates heterogeneous adoption driven by regional regulatory frameworks, variable reimbursement models, and differentiated hospital capabilities. In Western Europe, established cardiovascular programs and coordinated national health systems can expedite clinical rollouts and registry participation, while other jurisdictions in the region may face resource constraints that influence adoption timing. Policy emphasis on value-based care and national procurement programs often shapes commercial engagement and contracting approaches.

In the Asia-Pacific region, rapid investment in cardiovascular care capacity combined with a growing cohort of patients with advanced heart failure creates significant clinical interest. Regional manufacturing hubs and government initiatives to enhance domestic medical device capability also create favorable conditions for localized production and supply-chain collaboration. Across all regions, tailored clinician education, registry participation, and localized regulatory expertise are essential to translate device-level innovation into broad clinical impact.

Strategic company-level insights highlighting competitive positioning, innovation focus, and partnership structures shaping the maglev ventricular assist device arena

Leading device developers and specialized startups are differentiating through distinct combinations of clinical evidence generation, intellectual property around magnetic suspension and motor control, and manufacturing scale. Some players prioritize rapid clinical adoption by partnering with prominent cardiac centers to run investigator-led registries and early feasibility studies, while others concentrate on establishing resilient supply chains and scalable production capabilities that support broader commercial launches. Collaboration between engineering-focused firms and established cardiovascular device manufacturers accelerates time-to-clinic for complex subsystems while preserving regulatory rigor.

Investment patterns indicate that companies demonstrating an integrated pathway from bench to bedside-combining strong hemocompatibility data, ergonomically designed implant systems, and comprehensive post-implant support services-are more successful in securing strategic hospital partnerships. Furthermore, firms that develop modular platforms capable of supporting different therapy applications and patient anatomies have greater commercial flexibility. Across the competitive landscape, intellectual property strategies, quality system maturity, and the ability to demonstrate long-term reliability in real-world settings remain critical differentiators that influence partner selection and acquisition interest.

Actionable recommendations for industry leaders to align clinical evidence, manufacturing resilience, and commercial strategies for successful maglev device adoption

Focus on building robust clinical evidence pathways that combine prospective trials with comprehensive registries to capture both controlled outcomes and real-world performance metrics. Strengthening post-market surveillance and engaging key opinion leaders early in device development will accelerate clinical acceptance and provide the data necessary for payer discussions. Concurrently, invest in supplier qualification and regional manufacturing partnerships to reduce exposure to trade volatility and to maintain uninterrupted device availability for critical care settings.

Design devices with modularity and ease of implantation in mind to broaden the pool of implanting surgeons and to reduce procedural complexity. Align commercial models to the needs of hospitals and ambulatory surgical centers by offering training programs, remote monitoring services, and flexible service agreements that lower barriers to adoption. Finally, pursue strategic collaborations between engineering teams, clinicians, and regulatory experts to streamline submissions and to adapt evidence-generation plans to evolving regulatory expectations, thereby shortening the pathway from innovation to sustained clinical use.

Research methodology describing rigorous primary and secondary approaches, expert engagement, and cross-functional validation used to produce the analysis

This study synthesizes insights from a structured review of peer-reviewed clinical literature, regulatory filings, and device-specific technical documentation, paired with qualitative primary research through interviews with cardiac surgeons, heart failure specialists, regulatory affairs professionals, and manufacturing experts. Technical assessments included analysis of device architectures, hemocompatibility considerations, and implant procedural workflows. Supply chain evaluations examined supplier diversification strategies, manufacturing footprints, and logistics vulnerabilities in the context of recent trade policy shifts.

Cross-functional validation sessions were conducted with clinical advisors and industry experts to ensure that device performance characterizations and clinical pathway implications reflect practical realities. Regulatory pathway mapping incorporated recent guidance and post-market surveillance expectations to align evidence recommendations with contemporary requirements. Where appropriate, sensitivity analyses of supply chain scenarios were applied to evaluate operational resilience and strategic responses, and findings were integrated into actionable recommendations for commercial and clinical stakeholders.

Conclusion synthesizing the strategic implications of maglev ventricular assist technology for clinicians, manufacturers, and health system decision-makers

Maglev ventricular assist technology offers a compelling combination of engineering innovation and clinical promise, particularly in its potential to reduce mechanical wear and to improve hemocompatibility compared with legacy designs. Translating technological advantages into sustained clinical impact requires coordinated efforts in evidence generation, clinician education, and service delivery. Health systems and device developers that invest concurrently in clinical registries, surgical training, and supply chain robustness will be best positioned to realize the potential benefits for patients with advanced heart failure.

Moreover, evolving regulatory expectations and the changing trade environment necessitate proactive planning around post-market surveillance and strategic sourcing. Stakeholders who adopt a holistic approach-integrating engineering robustness, clinical validation, and commercial enablement-will accelerate adoption while managing risk. Ultimately, the successful rollout of maglev support systems depends not only on device performance but also on the ability of manufacturers and clinical partners to deliver consistent outcomes, scalable implantation pathways, and long-term patient support.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. MagLev Ventricular Assist Device Market, by Flow Type

• 8.1. Continuous Flow
  • 8.1.1. Axial Flow
  • 8.1.2. Centrifugal Flow
• 8.2. Pulsatile Flow

9. MagLev Ventricular Assist Device Market, by Device Type

• 9.1. Bivad
• 9.2. Lvad
• 9.3. Rvad

10. MagLev Ventricular Assist Device Market, by Therapy Application

• 10.1. Bridge To Recovery
• 10.2. Bridge To Transplant
• 10.3. Destination Therapy

11. MagLev Ventricular Assist Device Market, by Patient Age Group

• 11.1. Adult
• 11.2. Pediatric

12. MagLev Ventricular Assist Device Market, by End User

• 12.1. Ambulatory Surgical Centers
• 12.2. Hospitals

13. MagLev Ventricular Assist Device Market, by Distribution Channel

• 13.1. Online
• 13.2. Offline

14. MagLev Ventricular Assist Device Market, by Region

• 14.1. Americas
  • 14.1.1. North America
  • 14.1.2. Latin America
• 14.2. Europe, Middle East & Africa
  • 14.2.1. Europe
  • 14.2.2. Middle East
  • 14.2.3. Africa
• 14.3. Asia-Pacific

15. MagLev Ventricular Assist Device Market, by Group

• 15.1. ASEAN
• 15.2. GCC
• 15.3. European Union
• 15.4. BRICS
• 15.5. G7
• 15.6. NATO

16. MagLev Ventricular Assist Device Market, by Country

• 16.1. United States
• 16.2. Canada
• 16.3. Mexico
• 16.4. Brazil
• 16.5. United Kingdom
• 16.6. Germany
• 16.7. France
• 16.8. Russia
• 16.9. Italy
• 16.10. Spain
• 16.11. China
• 16.12. India
• 16.13. Japan
• 16.14. Australia
• 16.15. South Korea

17. United States MagLev Ventricular Assist Device Market

18. China MagLev Ventricular Assist Device Market

19. Competitive Landscape

• 19.1. Market Concentration Analysis, 2025
  • 19.1.1. Concentration Ratio (CR)
  • 19.1.2. Herfindahl Hirschman Index (HHI)
• 19.2. Recent Developments & Impact Analysis, 2025
• 19.3. Product Portfolio Analysis, 2025
• 19.4. Benchmarking Analysis, 2025
• 19.5. Abbott Laboratories
• 19.6. Berlin Heart GmbH
• 19.7. BiVACOR, Inc.
• 19.8. Calon Cardio-Technology Ltd.
• 19.9. CH Biomedical, Inc.
• 19.10. Cirtec Medical Corporation
• 19.11. Cleveland Heart, Inc.
• 19.12. Coridea, LLC
• 19.13. CorWave SA
• 19.14. Evaheart, Inc.
• 19.15. FineHeart SA
• 19.16. Leviticus Cardio Ltd.
• 19.17. Magenta Medical Ltd.
• 19.18. Medtronic plc
• 19.19. NuPulseCV, Inc.
• 19.20. ReinHeart TAH GmbH
• 19.21. Sun Medical Technology Research Corp.
• 19.22. Windmill Cardiovascular Systems, Inc.

LIST OF FIGURES

• FIGURE 1. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SHARE, BY KEY PLAYER, 2025
• FIGURE 3. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET, FPNV POSITIONING MATRIX, 2025
• FIGURE 4. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY FLOW TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 5. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DEVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY THERAPY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 7. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 9. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 11. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 13. UNITED STATES MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 14. CHINA MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

• TABLE 1. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 2. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY FLOW TYPE, 2018-2032 (USD MILLION)
• TABLE 3. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CONTINUOUS FLOW, BY REGION, 2018-2032 (USD MILLION)
• TABLE 4. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CONTINUOUS FLOW, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 5. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CONTINUOUS FLOW, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 6. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
• TABLE 7. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY AXIAL FLOW, BY REGION, 2018-2032 (USD MILLION)
• TABLE 8. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY AXIAL FLOW, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 9. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY AXIAL FLOW, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 10. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CENTRIFUGAL FLOW, BY REGION, 2018-2032 (USD MILLION)
• TABLE 11. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CENTRIFUGAL FLOW, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 12. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CENTRIFUGAL FLOW, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 13. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PULSATILE FLOW, BY REGION, 2018-2032 (USD MILLION)
• TABLE 14. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PULSATILE FLOW, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 15. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PULSATILE FLOW, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 16. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 17. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BIVAD, BY REGION, 2018-2032 (USD MILLION)
• TABLE 18. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BIVAD, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 19. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BIVAD, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 20. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY LVAD, BY REGION, 2018-2032 (USD MILLION)
• TABLE 21. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY LVAD, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 22. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY LVAD, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 23. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY RVAD, BY REGION, 2018-2032 (USD MILLION)
• TABLE 24. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY RVAD, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 25. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY RVAD, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 26. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY THERAPY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 27. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO RECOVERY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 28. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO RECOVERY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 29. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO RECOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 30. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO TRANSPLANT, BY REGION, 2018-2032 (USD MILLION)
• TABLE 31. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO TRANSPLANT, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 32. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO TRANSPLANT, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 33. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DESTINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 34. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DESTINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 35. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DESTINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 36. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 37. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
• TABLE 38. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 39. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 40. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
• TABLE 41. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 42. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 43. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 44. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 45. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 46. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 47. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 48. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 49. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 50. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 51. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 52. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 53. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 54. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 55. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 56. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 57. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 58. AMERICAS MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 59. AMERICAS MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY FLOW TYPE, 2018-2032 (USD MILLION)
• TABLE 60. AMERICAS MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
• TABLE 61. AMERICAS MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 62. AMERICAS MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY THERAPY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 63. AMERICAS MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 64. AMERICAS MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 65. AMERICAS MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 66. NORTH AMERICA MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 67. NORTH AMERICA MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY FLOW TYPE, 2018-2032 (USD MILLION)
• TABLE 68. NORTH AMERICA MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
• TABLE 69. NORTH AMERICA MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 70. NORTH AMERICA MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY THERAPY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 71. NORTH AMERICA MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 72. NORTH AMERICA MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 73. NORTH AMERICA MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 74. LATIN AMERICA MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 75. LATIN AMERICA MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY FLOW TYPE, 2018-2032 (USD MILLION)
• TABLE 76. LATIN AMERICA MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
• TABLE 77. LATIN AMERICA MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 78. LATIN AMERICA MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY THERAPY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 79. LATIN AMERICA MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 80. LATIN AMERICA MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 81. LATIN AMERICA MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 83. EUROPE, MIDDLE EAST & AFRICA MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY FLOW TYPE, 2018-2032 (USD MILLION)
• TABLE 84. EUROPE, MIDDLE EAST & AFRICA MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
• TABLE 85. EUROPE, MIDDLE EAST & AFRICA MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 86. EUROPE, MIDDLE EAST & AFRICA MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY THERAPY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 87. EUROPE, MIDDLE EAST & AFRICA MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 88. EUROPE, MIDDLE EAST & AFRICA MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 89. EUROPE, MIDDLE EAST & AFRICA MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 90. EUROPE MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 91. EUROPE MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY FLOW TYPE, 2018-2032 (USD MILLION)
• TABLE 92. EUROPE MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
• TABLE 93. EUROPE MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 94. EUROPE MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY THERAPY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 95. EUROPE MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 96. EUROPE MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 97. EUROPE MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 98. MIDDLE EAST MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 99. MIDDLE EAST MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY FLOW TYPE, 2018-2032 (USD MILLION)
• TABLE 100. MIDDLE EAST MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
• TABLE 101. MIDDLE EAST MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 102. MIDDLE EAST MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY THERAPY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 103. MIDDLE EAST MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 104. MIDDLE EAST MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 105. MIDDLE EAST MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 106. AFRICA MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 107. AFRICA MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY FLOW TYPE, 2018-2032 (USD MILLION)
• TABLE 108. AFRICA MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
• TABLE 109. AFRICA MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 110. AFRICA MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY THERAPY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 111. AFRICA MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 112. AFRICA MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 113. AFRICA MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 114. ASIA-PACIFIC MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 115. ASIA-PACIFIC MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY FLOW TYPE, 2018-2032 (USD MILLION)
• TABLE 116. ASIA-PACIFIC MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
• TABLE 117. ASIA-PACIFIC MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 118. ASIA-PACIFIC MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY THERAPY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 119. ASIA-PACIFIC MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 120. ASIA-PACIFIC MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 121. ASIA-PACIFIC MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 122. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 123. ASEAN MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 124. ASEAN MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY FLOW TYPE, 2018-2032 (USD MILLION)
• TABLE 125. ASEAN MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
• TABLE 126. ASEAN MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 127. ASEAN MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY THERAPY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 128. ASEAN MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 129. ASEAN MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 130. ASEAN MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 131. GCC MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 132. GCC MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY FLOW TYPE, 2018-2032 (USD MILLION)
• TABLE 133. GCC MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
• TABLE 134. GCC MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 135. GCC MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY THERAPY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 136. GCC MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 137. GCC MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 138. GCC MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 139. EUROPEAN UNION MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 140. EUROPEAN UNION MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY FLOW TYPE, 2018-2032 (USD MILLION)
• TABLE 141. EUROPEAN UNION MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
• TABLE 142. EUROPEAN UNION MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 143. EUROPEAN UNION MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY THERAPY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 144. EUROPEAN UNION MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 145. EUROPEAN UNION MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 146. EUROPEAN UNION MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 147. BRICS MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 148. BRICS MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY FLOW TYPE, 2018-2032 (USD MILLION)
• TABLE 149. BRICS MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
• TABLE 150. BRICS MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 151. BRICS MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY THERAPY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 152. BRICS MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 153. BRICS MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 154. BRICS MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 155. G7 MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 156. G7 MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY FLOW TYPE, 2018-2032 (USD MILLION)
• TABLE 157. G7 MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
• TABLE 158. G7 MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 159. G7 MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY THERAPY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 160. G7 MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 161. G7 MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 162. G7 MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 163. NATO MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 164. NATO MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY FLOW TYPE, 2018-2032 (USD MILLION)
• TABLE 165. NATO MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
• TABLE 166. NATO MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 167. NATO MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY THERAPY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 168. NATO MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 169. NATO MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 170. NATO MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 171. GLOBAL MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 172. UNITED STATES MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 173. UNITED STATES MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY FLOW TYPE, 2018-2032 (USD MILLION)
• TABLE 174. UNITED STATES MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
• TABLE 175. UNITED STATES MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 176. UNITED STATES MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY THERAPY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 177. UNITED STATES MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 178. UNITED STATES MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 179. UNITED STATES MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 180. CHINA MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 181. CHINA MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY FLOW TYPE, 2018-2032 (USD MILLION)
• TABLE 182. CHINA MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
• TABLE 183. CHINA MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 184. CHINA MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY THERAPY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 185. CHINA MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 186. CHINA MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 187. CHINA MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)